Get started
Author

Cyrille Hulin

Observed names: C Hulin, C. Hulin, C. Hullin, Cyrille HULIN, Cyrille Hullin, HULIN, Cyrille, Hulin C, Hulin Cyrille, Hulin, C, Hulin, C., Hulin, C. (C.), Hulin, Cyrille
Observed institutions: Université de Tours, Hôpital Necker-Enfants Malades, Roswell Park Comprehensive Cancer Center, Cliniques Universitaires Saint-Luc, University Medical Center Groningen, Karolinska University Hospital, Ankara University, Université de Bordeaux, Inserm, National and Kapodistrian University of Athens, Université de Lille, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire Vaudois, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nice, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Tours, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Régional et Universitaire de Nancy, Hôpital Saint-Antoine, St. Antonius Ziekenhuis, Centre Hospitalier Universitaire de Reims, Institut de Cancérologie de l'Ouest, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Caen Normandie, CHU Dijon Bourgogne, Amgen (United Kingdom), Hôpital Cardiologique du Haut-Lévêque, Hôpital Rangueil, Hôpital Edouard Herriot, Intergroupe Francophone du Myélome, Universitair Ziekenhuis Brussel, Institut Claudius Regaud, Centre Hospitalier Régional Universitaire de Brest, Hôpital Purpan, Swiss Group For Clinical Cancer Research, Erasmus MC Cancer Institute, Institut Paoli-Calmettes, Amsterdam University Medical Centers, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Rennes, Hôpital Albert Michallon, Centre Henri Becquerel, Université de Nantes, University of Turin, University of Nebraska Medical Center, Institut Curie, Sapienza University of Rome, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Nantes Université
ORCID: 0000-0002-3749-5161
Observed ORCID: 0000-0002-3749-5161
OpenAlex ID: A5089853890
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
2017 · Michel Attal, Valerie Lauwers-Cances, et al. · New England Journal of Medicine · 1,251
PDF
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
2012 · Michel Attal, Valerie Lauwers-Cances, et al. · New England Journal of Medicine · 1,158
PDF
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
2019 · Thierry Facon, Shaji Kumar, et al. · New England Journal of Medicine · 1,014
PDF
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
2003 · Michel Attal, Jean-Luc Harousseau, et al. · New England Journal of Medicine · 973
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
2019 · Philippe Moreau, Michel Attal, et al. · The Lancet · 967
PDF
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
2007 · Hervé Avet-Loiseau, Michel Attal, et al. · Blood · 911
PDF
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
2007 · Thierry Facon, Jean Yves Mary, et al. · The Lancet · 869
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
2019 · Sagar Lonial, Hans C Lee, et al. · The Lancet Oncology · 807
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
2014 · Lotfi Benboubker, Meletios A. Dimopoulos, et al. · New England Journal of Medicine · 794
PDF
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
2011 · S K Kumar, J H Lee, et al. · Leukemia · 720
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
2017 · Philip L. McCarthy, Sarah A. Holstein, et al. · Journal of Clinical Oncology · 696
PDF
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
2006 · M. Attal, J.-L. Harousseau, et al. · Blood · 667
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
2019 · Michel Attal, Paul G Richardson, et al. · The Lancet · 645
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2023 · Pieter Sonneveld, Meletios A. Dimopoulos, et al. · New England Journal of Medicine · 588
PDF
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010 · Jean-Luc Harousseau, Michel Attal, et al. · Journal of Clinical Oncology · 532
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010 · Hervé Avet-Loiseau, Xavier Leleu, et al. · Journal of Clinical Oncology · 424
PDF
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
2018 · Aurore Perrot, Valerie Lauwers-Cances, et al. · Blood · 417
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
2021 · Philippe Moreau, Meletios-Athanasios Dimopoulos, et al. · The Lancet · 391
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009 · Cyrille Hulin, Thierry Facon, et al. · Journal of Clinical Oncology · 381
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
2021 · Thierry Facon, Shaji K Kumar, et al. · The Lancet Oncology · 371
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006 · Frederic Garban, Michel Attal, et al. · Blood · 368
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
2021 · Meletios A Dimopoulos, Evangelos Terpos, et al. · The Lancet Oncology · 341
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
2006 · Jean-Luc Harousseau, Michel Attal, et al. · PubMed · 333
Prospective Evaluation of Magnetic Resonance Imaging and [ 18 F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
2017 · Philippe Moreau, Michel Attal, et al. · Journal of Clinical Oncology · 326
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
2011 · Philippe Moreau, Herve Avet-Loiseau, et al. · Blood · 303
Works count: 583
Citation count: 27,830
H-index: 74
I10-index: 211
Year
Topic
Type